MiPT

Discovery

Repke, Grotjahn, and Shulgin first described MiPT in 1985 in the Journal of Medicinal Chemistry, as part of a series synthesizing eight N-methyl-N-isopropyltryptamine analogs with varying ring substituents.^[2] The study established a key principle: placing a bulky isopropyl group on the terminal amine nitrogen protected tryptamines from monoamine oxidase degradation, making them orally active without MAOI co-administration — a limitation that had defined DMT.^[2] Multiple secondary sources cite 1981 as the date of first synthesis, but no published record from that year has been identified; the 1981 date likely refers to unpublished laboratory work.^[2]

Characterization and documentation

Alexander Shulgin provided extended documentation of MiPT in TiHKAL: Tryptamines I Have Known and Loved (1997), entry #47.^[3] The entry records two synthetic routes, establishes the oral dosage range at 10–25 mg with a duration of 3–4 hours, and includes detailed self-experiment narratives across multiple dose levels.^[3] Shulgin noted the compound's unusual physical stability — the freebase resists air oxidation far better than most tryptamines.^[3]

Modern status

MiPT appeared as a novel psychoactive substance in Europe by approximately 2005 but has remained exceptionally rare.citation needed Unlike its ring-substituted relatives 5-MeO-MiPT and 5-MeO-DiPT, which have generated forensic case literature, MiPT has produced virtually no clinical or forensic reports — consistent with its limited prevalence.citation needed

Structural class

MiPT belongs to the substituted tryptamine family — compounds built on an indole ring connected to an ethylamine side chain at the 3-position. Its defining feature is an asymmetric N,N-dialkyl substitution: one methyl group and one isopropyl group on the terminal amine nitrogen.^[3]

This asymmetry is pharmacologically decisive. The bulky isopropyl group shields the molecule from monoamine oxidase degradation during first-pass metabolism, granting oral bioavailability that the symmetrical N,N-dimethyl structural analog (DMT) lacks.^[2][3] MiPT is the unsubstituted-ring parent in a series that includes 4-HO-MiPT and 5-MeO-MiPT.^[2]

Molecular properties

MiPT contains no chirality centers and exists as a single achiral species.

Physical properties

MiPT freebase is a colorless oil that spontaneously crystallizes, with a melting point of 82–83 °C.^[3] The compound is unusually stable to air oxidation — a distinctive property among tryptamine freebases, which typically decompose rapidly when exposed to light and oxygen.^[3][6] No solubility, partition coefficient, or degradation pathway data have been published.

Mechanism of action

MiPT produces its psychedelic effects primarily through partial agonism at serotonin 5-HT₂A receptors.^[1] It activates these receptors with moderate potency but does not reach the full signaling intensity of serotonin itself, producing partial rather than full activation.^[1]

Notably, MiPT shows no meaningful activity at 5-HT₁A receptors^[1] — contradicting earlier classifications and distinguishing it from 5-substituted tryptamines like 5-MeO-MiPT, which consistently activate 5-HT₁A.^[7]

MiPT also enters neurons through the SERT (SERT) and VMAT2 (VMAT2), functioning as a substrate rather than a blocker at both.^[8] This mechanism — analogous to how amphetamine enters neurons via the DAT — may allow intraneuronal accumulation, though the functional consequences remain unknown.^[8]

Pharmacokinetics

No human pharmacokinetic studies exist for MiPT. Key parameters — time to peak blood levels, plasma half-life, bioavailability, and protein binding — have not been measured.

Metabolic pathways are inferred from the close structural analog 5-MeO-MiPT, whose primary routes include N-demethylation and hydroxylation, with additional N-oxide formation.^[9] Enzyme involvement is inferred from related tryptamines, where CYP2D6 and CYP3A4 are the principal metabolizing enzymes.^[10] Until substance-specific data are available, CYP2D6 and CYP3A4 involvement should be assumed for MiPT.inferred

Where it acts

No neuroimaging or electrophysiological data exist for MiPT specifically. Based on its established 5-HT₂A partial agonism,^[1] its primary neural effects are expected in the prefrontal cortex, where 5-HT₂A receptors are densely expressed.citation needed Activation of these receptors disrupts thalamocortical gating — the brain's filtering system for sensory and cognitive information — increasing cross-talk between brain regions that normally operate independently.citation needed

MiPT's substrate behavior at SERT and VMAT2^[8] raises the additional possibility of intraneuronal sigma-1 receptor activation, which modulates calcium signaling and gene expression.^[8] Whether this pathway contributes meaningfully to MiPT's effects is unknown.

Why it matters

The REBUS model proposes that 5-HT₂A agonism loosens the brain's reliance on established expectations, allowing raw sensory input greater influence on conscious experience.citation needed MiPT's cognitive-dominant, visual-sparse profile could test this model — the theory would need to explain substantial cognitive disruption with minimal perceptual distortion.

Psychedelics are increasingly recognized as psychoplastogens — compounds that promote structural neural growth. MiPT's partial agonism and biased signaling at 5-HT₂A^[1] raise the question of whether partial activation reaches the threshold for neuroplastic effects.citation needed

Toxicity

No lethal dose, therapeutic index, or controlled toxicity data exist for MiPT in any species.safety citation needed No case reports of adverse events, poisoning, or overdose specific to MiPT have been published.

• Cardiovascular stimulation: increased heart rate and blood pressure at higher doses
• Temperature dysregulation: overheating is possible, particularly with physical exertion or warm environments
• Serotonin syndrome: risk elevated when combined with serotonergic agents

Psychological risks

Acute psychological distress — anxiety, panic, paranoia, and confusion — occurs with all classical psychedelics and is expected with MiPT.safety citation needed No substance-specific prevalence data exist.

Hallucinogen persisting perception disorder (HPPD) has not been reported with MiPT, though the evidence base is too thin to assess actual risk.

Individuals with personal or family histories of psychotic disorders or bipolar disorder face elevated risk of psychosis or psychiatric destabilization with any 5-HT₂A agonist.safety citation needed

Tolerance and dependence

MiPT does not produce physical dependence. No withdrawal has been documented for MiPT or any closely related tryptamine.

Rapid tolerance develops after a single dose through downregulation of 5-HT₂A receptors in the frontal cortex.^[4] Cross-tolerance extends to other serotonergic psychedelics including LSD, psilocybin, and DMT.^[12]

Tryptamine-derived psychedelics may develop less tolerance than phenethylamine-derived psychedelics, suggesting MiPT's tolerance buildup could be somewhat less pronounced than LSD-class compounds.^[13] Rapid tolerance itself limits reinforcing properties, further reducing abuse liability.

MAOIs: Both irreversible and reversible MAOIs would markedly potentiate and prolong MiPT's effects by blocking metabolic degradation while increasing serotonin availability. Serotonin syndrome risk is severe.^[5] This applies to pharmaceutical MAOIs (phenelzine, tranylcypromine, moclobemide) and to β-carboline MAOIs in ayahuasca preparations.

SSRIs: Serotonin syndrome risk exists when combining any 5-HT₂A agonist with SSRIs.^[5] SSRIs may also blunt psychedelic effects through chronic receptor downregulation.

Lithium: Lithium combined with serotonergic psychedelics is associated with seizures and severe neurological reactions.safety citation needed This is a class-level absolute contraindication.

Stimulants: Cocaine, amphetamines, or methylphenidate increase cardiovascular load. The 5-MeO-MiPT forensic case involved polydrug use with cocaine and methylphenidate.^[9]

CYP2D6/CYP3A4 inhibitors: Based on inferred metabolic pathways, potent inhibitors of these enzymes could increase MiPT exposure and prolong effects.inferred

Cannabis: Anecdotally reported to intensify and prolong psychedelic effects unpredictably. No MiPT-specific data exist.citation needed

Contraindications

No substance-specific contraindication studies exist. The following are inferred from class-level pharmacology.

Absolute:

• Concurrent MAOI use — serotonin syndrome and dangerous potentiation
• Concurrent lithium therapy — seizure risk
• Personal history of psychotic disorders — psychosis precipitation
• Personal history of bipolar I disorder — manic episode triggering

Relative:

• Concurrent SSRI or SNRI use — serotonin syndrome risk and attenuated effects
• Family history of psychotic disorders — elevated vulnerability
• Heart conditions (high blood pressure, irregular heartbeat, heart failure) — cardiovascular stimulation at higher doses
• Pregnancy and breastfeeding — no safety data exist
• Liver impairment — inferred CYP2D6/CYP3A4 metabolism may produce elevated exposureinferred

MiPT occupies a legally ambiguous position in most jurisdictions. It is not specifically scheduled under most national drug control frameworks, but its structural relationship to scheduled tryptamines exposes it to structural analog or generic provisions in several countries.

Legal status is subject to change. The Federal Analog Act in the United States and generic substance definitions in the United Kingdom and potentially Australia create de facto control even where MiPT is not explicitly named. Possession or supply for human consumption may constitute a criminal offense in these jurisdictions regardless of explicit scheduling status.